Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs

The ability to block specific cytokine pathways has revealed pathophysiological differences among autoimmune diseases (e.g., the efficacy of TNF inhibitors in arthritides and inflammatory bowel disorders and their inefficacy in giant-cell arteritis and multiple sclerosis), providing a framework for...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 385; no. 7; pp. 628 - 639
Main Authors Schett, Georg, McInnes, Iain B, Neurath, Markus F
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 12.08.2021
Subjects
Allergy
Arteritis
Autoimmune Disease
Autoimmune diseases
Classification
Cytokines
Disease
Drug therapy
Fibroblasts
Gastroenterology
Genetics
Immunity
Immunology
Immunology General
Inflammation
Inflammatory Bowel Disease
Inflammatory diseases
Multiple sclerosis
Osteoporosis
Pathogenesis
Reclassification
Rheumatoid Arthritis
Rheumatology
Rheumatology General
Skin
Tumor necrosis factor
Tumor necrosis factor-TNF
Vasculitis
Online AccessGet full text

Cover

More Information
Summary:The ability to block specific cytokine pathways has revealed pathophysiological differences among autoimmune diseases (e.g., the efficacy of TNF inhibitors in arthritides and inflammatory bowel disorders and their inefficacy in giant-cell arteritis and multiple sclerosis), providing a framework for reclassification.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMra1909094